Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHunger persisting at the 5mg dose of Mounjaro is more common than most people expect. Many patients find appetite suppression builds gradually across the titration schedule, and 5mg is still an early stage of that process — not the point where the medicine reaches its full effect. That said, it is a prescription-only medicine, and what you experience at any dose should be discussed with your prescribing clinician rather than adjusted without guidance. The sections below explain the biology behind this, what tends to change as treatment progresses, and what is worth flagging to your prescriber rather than simply waiting out.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro contains tirzepatide, a medicine that activates two receptor pathways involved in appetite and blood-sugar regulation. The GIP and GLP-1 receptors work together to slow gastric emptying, increase feelings of fullness after eating, and gradually reduce the brain's drive to seek food. The NHS page on tirzepatide explains this dual mechanism and what to expect from treatment.
Here is the part that catches people off guard: those effects are dose-dependent. The 2.5mg starting pen exists to let your body adjust to the medicine with minimal side effects. Moving to 5mg is the first real therapeutic step, but clinical trials consistently showed that the largest reductions in appetite and body weight occurred at higher maintenance doses. In the SURMOUNT-1 trial published in the New England Journal of Medicine, average weight loss at 15mg over 72 weeks reached around 20–21%, figures that reflect months of progressive titration, not the effect of an early dose.
So if food feels tempting at 5mg, that is not a sign of treatment failure. It is a sign that your body's appetite signals have not yet encountered the dose at which tirzepatide tends to quiet them most effectively. Some people notice a meaningful shift at 5mg; others find the change only becomes obvious at 7.5mg or beyond. Both experiences are within the normal range. If you are curious about why hunger persists specifically on the 5mg dose, that page goes into the physiological reasons in more detail. You can also read more about the 5mg dose in detail to understand where it sits in the overall schedule.
One misconception worth gently setting aside: some people assume that feeling hungry on Mounjaro means they are overeating or somehow resisting the medicine. The more likely explanation is simpler. At 5mg, gastric emptying has begun to slow, but the full recalibration of appetite hormones that the higher doses produce has not yet landed. The hunger you feel is largely physiological, not a failure of willpower.
That said, there is a practical distinction worth making. Genuine appetite (wanting food because your body needs fuel) is different from the habit-driven urge to eat at certain times or in response to boredom or stress. Mounjaro tends to reduce both over time, but at 5mg you may still experience the second category fairly strongly. Protein-adequate meals, consistent mealtimes, and staying well-hydrated can reduce the noise of habit-driven hunger while the medicine continues to build its effect. Our overview of weight-loss treatment covers the lifestyle foundations that support GLP-1 therapy at every stage.
If you are eating very little and still feeling hungry, that is a different signal and worth raising directly. Undereating can become its own problem on GLP-1 treatment, particularly if protein intake drops. A prescriber or dietitian can help you set a realistic daily target rather than guessing.
Hunger alone at 5mg is expected and rarely requires urgent action. There are situations, though, where it is worth getting in touch with your prescribing team rather than waiting for the next scheduled review. These include: hunger severe enough that you are not achieving any reduction in food intake after several weeks at 5mg; a sense that the medicine is having no effect whatsoever on cravings or portion size; or hunger accompanied by symptoms you didn't have before treatment, such as persistent nausea alongside strong appetite, which can occasionally indicate your dose-timing or injection technique needs attention.
If nausea has been part of your experience alongside the hunger, the guidance on feeling sick at 5mg covers the most common causes and what tends to help. Those two symptoms together are more common than people realise and often have a straightforward explanation. Dose changes, missed injections and injection site habits all play a role, your prescriber can review the specifics with you. Our clinical team profiles, including Mostafa Damghani, give a sense of who is reviewing your case at nume (sorry, at nume) the prescriber, not a system.
The NHS tirzepatide medicines page is a reliable reference if you want to cross-check what is considered a normal experience versus a side effect worth reporting. Any suspected side effect can also be logged via the MHRA's Yellow Card reporting scheme, which helps regulators track real-world experiences with newer medicines.
For most people, the answer to hunger at 5mg is time and titration. The titration schedule exists precisely because the body needs a stepped introduction. Each four-week dose phase allows your system to settle at one level before the prescriber considers moving to the next. Across the SURMOUNT programme, involving thousands of adults, appetite suppression and weight loss both deepened consistently as participants moved through the dose steps. That trajectory is the intended design of the treatment. It also mirrors what many patients report when looking back: feeling hungry on the 2.5mg starting dose is extremely common, and for most people that hunger gradually eases as the dose steps up. Many people also find themselves wondering whether tirzepatide has wider hormonal effects as they progress through treatment, and the question of whether tirzepatide increases testosterone is one that comes up more often than you might expect.
If you are concerned about cost as the dose increases (and it is a fair question given that higher-dose pens carry a higher list price) the background on Eli Lilly's UK price changes gives context on what has shifted and why. What does not change at nume (at nume) is the structure: one transparent price covering consultation, prescription, and next-working-day delivery, reviewed clinically at each repeat. No surprises mid-treatment. If you have questions outside of a scheduled review, the support team is available seven days a week.
Once you are better informed about what 5mg does and does not do, the free consultation is the right next step if you are not yet a patient, or if you want a clinical review of how your current treatment is going.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.